person
Dirk R.
- Country
- Germany
- Department
- Department for Pediatric Hematology and Oncology
Research Overview
assignment
2
Clinical Trials ·
- A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetate in Paediatric Subjects from Birth to <18 Years of Age, Receiving Systemic Antifungals as Prophylaxis for Invasive Fungal Infection or to Treat a Suspected or Confirmed Fungal Infection
- Evaluation of Luveltamab Tazevibulin (STRO-002) Monotherapy in Pediatric Patients with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
1
Sites with multiple studies
Has run more than one trial at 1 of 15 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of pediatric blood cancers, with particular focus on acute myeloid leukemia (AML) and anaplastic large cell lymphoma (ALCL).
- FLT3-mutated AML treatment approaches
- ALK-positive lymphoma management
- Refractory leukemia interventions
Targeted Therapies
Expertise in implementing precision medicine approaches for pediatric cancers, focusing on specific molecular pathways and genetic mutations.
- MAPK/SRC signaling pathway treatments
- IL-7R/JAK-STAT pathway interventions
- Novel therapeutic combinations
Solid Tumors
Active involvement in treating pediatric solid malignancies, with specialized focus on rhabdomyosarcoma and inflammatory myofibroblastic tumors.
- Advanced sarcoma treatments
- Multimodal therapy approaches
- Innovative radiation protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.